OvaScience Announces Proposed Public Offering of Common Stock

WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, announced today that it has commenced an underwritten
public offering of shares of its common stock. OvaScience intends to
grant the underwriters a 30-day option to purchase additional shares of
the common stock to cover over-allotments, if any. All of the shares in
the offering will be sold by OvaScience.

Leerink Partners LLC is acting as the sole book-running manager of the
offering and H.C. Wainwright & Co. is acting as a co-manager of the
offering. The offering is subject to market and other conditions and
there can be no assurances as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.

OvaScience intends to use the net proceeds from this offering to fund
the commercial expansion of the AUGMENTSM treatment in our
key regions, Japan and Canada, the ongoing pre-commercial activities for
the OvaPrimeSM treatment and the OvaTureSM
treatment, and working capital and other general corporate purposes.

The public offering will be made pursuant to a shelf registration
statement on Form S-3 that was previously filed with and declared
effective by the Securities and Exchange Commission (“SEC”). A
preliminary prospectus supplement and accompanying base prospectus
relating to and describing the terms of the offering has been filed with
the SEC. The offering is being made only by means of a prospectus and
related prospectus supplement, copies of which, when available, may be
obtained from Leerink Partners LLC, Attention: Syndicate Department, One
Federal Street, 37th Floor, Boston, MA, 02110, or by phone at
1-800-808-7525, ext. 6142, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About OvaScience
OvaScience, Inc. (NASDAQ: OVAS) is a global
fertility company dedicated to improving treatment options for women
around the world. OvaScience is discovering, developing and
commercializing new fertility treatments because it believes women
deserve more options. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPCSM) cells –
immature egg cells found inside the protective ovarian lining. The
AUGMENTSM treatment, a fertility option specifically designed
to improve egg health, is available in certain IVF clinics in select
international regions. OvaScience has commenced a non-commercial
preceptorship training program with the OvaPrimeSM treatment,
which could increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S.

Forward-Looking Statements
This press release includes
forward-looking statements including statements about OvaScience’s
proposed public offering of securities and the intended use of proceeds
therefrom. Actual results may differ materially from those indicated by
these forward-looking statements as a result of various important
factors, including risks related to:
the possibility that
international IVF clinics that OvaScience works with may determine not
to provide or continue providing or studying the AUGMENT treatment or
OvaPrime treatment, or to delay providing such treatments, based on
clinical efficacy, safety or commercial, logistic, regulatory,
enrollment, inability to agree on commercial terms, or other reasons;
the science underlying the company’s treatments (including the AUGMENT,
OvaPrime and OvaTure treatments), which is unproven; the Company’s
ability to obtain regulatory approval or licenses where necessary for
its treatments; OvaScience’s ability to develop its treatments on the
timelines it expects, if at all; the Company’s ability to commercialize
its treatments, on the timelines it expects, if at all; as well as those
risks more fully discussed in the “Risk Factors” section of its most
recently filed Annual Report on Form 10-K and Quarterly Reports on Form
10-Q. The forward-looking statements contained in this press release
reflect the Company’s current views with respect to future events. It
anticipates that subsequent events and developments will cause its views
to change. However, while it may elect to update these forward-looking
statements in the future, it specifically disclaims any obligation to do
so. These forward-looking statements should not be relied upon as
representing OvaScience’s view as of any date subsequent to the date
hereof.

## ## ##

Contacts

OvaScience
Rebecca J. Peterson, 617-420-8736
rpeterson@ovascience.com